Manganese belongs to a group of agents called "transitional metals" that are known to induce occupational asthma. How ever, well-documented cases of manganese-induced asthma have been lacking thus far. We have discussed a case of a 42-year-old non-smoking welder with work-related dyspnea. A number of clinical procedures were performed including clinical examination, routine laboratory tests, total serum IgE, skin prick tests to common aeroallergens and manganese nitrate, resting spirometry test, histamine challenge, and a single-blind, placebo-controlled specifi c inhalation challenge with 0.1% manganese chloride solution. Clinical fi ndings and laboratory test results remained normal but a signifi cant bronchial hyperreactivity was found. During the specifi c inhalation challenge, dyspnea and a signifi cant decrease in forced expiratory volume (FEV1) were observed. An increased proportion of eosinophils and basophils in induced sputum could also be noted at 4 and 24 h after the challenge. The argument for recognizing the condition as occupational asthma was a positive clinical response to the specifi c challenge test as well as the morphological changes found in induced sputum. To our knowledge, this is the fi rst well-documented case of manganese-induced occupational asthma
INTRODUCTION
Manganese is a silver-white, extremely hard metal. It is used in the metallurgic industry to improve the strength, toughness and hardness of different alloys, and their rolling and forging qualities. This metal is also used in the manufacture of arc welding electrodes; in the ceramic industry to colorize glass and ceramic products, in the dry-battery industry, and also in the manufacture of dyes, paints, fungicides, and pharmaceuticals. Workers are rarely exposed to pure manganese, more often to its salts.
Excess exposure to manganese is toxic. There are two possible pathways of manganese toxicity. The fi rst one is neurotoxicity, which is responsible for the development of Parkinson's-like disease. The second one, related to the respiratory system, is the manganese-induced pneumonia [1] . Longlasting exposure can also be associated with pulmonary disorders such as interstitial lung fi brosis [2] . Up to now, the only case of manganese-induced occupational asthma was that described by Saakadze et al. in 1977 [3] .
METHODS
We report on a case of a 42-year-old never-smoking welder admitted to the Department of Occupational Diseases with a suspected occupational asthma. He had been working for 20 years at the train factory. His job tasks included welding for at least four hours per day. The patient was exposed to industrial aerosols containing manganese, crystalline silica, nitric oxide, carbon oxide, and iron oxide. After 10 years of working as a welder, he developed recurrent non-productive cough. Four years since then, he experienced the fi rst episode of dyspnea. On admission, he had a history of recurrent dyspnea with wheezing that
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in induced sputum could be noted after manganese chloride exposure at 4 and 24 h after the challenge (Table 1) . Placebo test did not produce any clinical, spirometric, or signifi cant cell proportion changes. The controls were two volunteers: a 39-year-old male with atopic asthma due to Dermatophagoides pteronyssinus and a 34-year-old healthy male. Both of them were subjected to specifi c inhalation challenge with 0.1% manganese chloride solution under similar conditions. None of the examined subjects developed clinical symptoms after usually occurred after 30-60 minutes of welding, over the period of the last six years. As reported by his GP, a higher than 20% variability in PEFR could be observed on the days the patient had been exposed, compared to the days he stayed away from work. We performed a clinical examination, routine laboratory testing, total serum IgE (Uni-CAP system Pharmacia Dia gnostics, Uppsala, Sweden), skin prick tests (SPTs) to common aeroallergens (dust mites, tree and grass pollens, molds, feathers) (Allergopharma, Germany) and to 0.01%, 0.1% and 1% solutions of manganese nitrate, as well as resting spirometry and histamine challenge test (Mijnhardt spirometer, The Netherlands). After that, the patient was subjected to a single-blind, placebo-controlled specifi c inhalation challenge with 0.1% manganese chloride solution. The test with placebo (1% potassium chloride solution) was performed two days before the specifi c challenge. Both the allergen and placebo were administered by a nebulizer for 5 minutes. Cellular composition of induced sputum was analyzed. Induced sputum samples were collected 10 min, before the provocation and 4 h and 24 h afterwards. The processing of induced sputum has been described elsewhere [4] .
RESULTS
The clinical and laboratory fi ndings (including chest x-ray) were normal. Total serum IgE was low (31.36 KU/l). SPTs to common aeroallergens and to 0.01%, 0.1% and 1% solutions of manganese nitrate were negative. Resting spirometry varied from normal to a mild obstruction: FEV1 from 3.55 l (85% predictive values) to 2.54 l (57%), FVC from 4.34 l (80%) to 5.98 l (115%). Histamine challenge revealed signifi cant bronchial hyperreactivity (PC 20 = 0.5 mg/ml). On the day of specifi c challenge, resting spirometry was as follows: FEV1 2.76 l (66%), FVC 5.31 l (104%). Five minutes after manganese chloride inhalation was over, dyspnea occurred, and a 45% decrease in forced expiratory volume (FEV1), dropping down to 55% at 1 h, and slightly rising to 35% at 24 h was observed (Fig. 1) . Also an increase in the proportion of eosinophils and basophils [5] [6] [7] . However, to our knowledge, the presently described condition is the fi rst well-documented case of manganese-induced occupational asthma. The diagnosis was based on the clinical response to specifi c challenge and the accompanying changes in induced sputum. An in-depth analysis of the report by Saskaadze who described what seemed to have been a manganese-induced occupational asthma revealed some issues that may have produced a false conclusion from the study. Saskaadze et al. used a 20% solution of manganese chloride for the provocation test, which seems to be too hypertonic for the inhalation test. It is plausible that such a solution could produce the bronchial spasm because of its hypertonity rather than an allergic reaction. Moreover, no placebo control or infl ammatory cell assessment was performed, which could confi rm the allergic nature of the bronchoconstriction.
